Fatty acid oxidation inhibitors are a new potent class of drugs used in treatment of stable angina pectoris and an addition in treatment of chronic heart failure.
Drugs edit
- CPT-I inhibitors: etomoxir, oxfenicine, perhexiline
CPT-I (carnitine palmitoyl transferase) converts fatty acyl-CoA to fatty acyl-carnitine. - Carnitine biosynthesis inhibitor: mildronate[1]
- 3-KAT inhibitors: trimetazidine
3-KAT (3-ketoacyl-coenzyme A thiolase) inhibitors directly inhibits fatty acid beta-oxidation. - pFOX directly inhibits fatty acid beta-oxidation.[2]
References edit
- ^ Liepinsh, E; Vilskersts, R; Loca, D; et al. (December 2006). "Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction". J. Cardiovasc. Pharmacol. 48 (6): 314–9. doi:10.1097/01.fjc.0000250077.07702.23. PMID 17204911.
- ^ Partial fatty acid oxidation inhibitors: a potentially new class of drugs for heart failure; European Journal of Heart Failure 4 2002. 3-6; http://eurjhf.oxfordjournals.org/content/4/1/3.full.pdf+html Archived 2013-08-21 at the Wayback Machine